Kaletra
Developed to manage HIV and indicated to target the replication of the virus in the body, supporting immune system health.
Strengths: 200/50mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Lopinavir / Ritonavir
- Therapeutic class
Antiretroviral
- Pharmacological class
Protease Inhibitor
- Precautions and warnings
monitor liver function; maintain consistent adherence to avoid drug resistance
- Minor side effects
nausea; vomiting; diarrhoea
- Moderate side effects
dyslipidaemia; abdominal pain; fatigue
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
AbbVie
- Onset Time
not applicable (chronic use)
- Duration
not applicable
- Storage instructions
Store at room temperature below 25°C.
- Drug interactions
st. john's wort; statins; oral contraceptives
- Age restrictions
As prescribed by an HIV specialist.
Contraindications
severe hepatic impairment; hypersensitivity to components; concurrent use of rifampicin
Serious side effects
pancreatitis — requires immediate medical attention; hepatotoxicity — requires immediate medical attention
Patient summary
Developed to manage HIV and indicated to target the replication of the virus in the body, supporting immune system health.
Mechanism of action
Kaletra contains a protease inhibitor that stops the HIV-1 protease enzyme from cleaving viral precursor proteins, which is essential for producing mature, infectious virus particles. Ritonavir acts as a pharmacokinetic booster, inhibiting the metabolism of lopinavir to maintain higher blood concentrations.
Pregnancy and breastfeeding
Pregnancy: benefit-risk assessment required. Breastfeeding: not recommended for HIV patients.
Kaletra
Developed to manage HIV and indicated to target the replication of the virus in the body, supporting immune system health.
Editorial Notes
- Active ingredient(s): Lopinavir, Ritonavir
- Listed indication(s): HIV Infection
Available option
- 60 tablets - 200/50 mg984-200-50-mg-17921